

MODIFIED FORM PTO-1449 (REV. 6-89)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO.: NMT-8440		SERIAL No. 10/716,929	
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT			APPLICANT(S): Rekha Bansal
		<i>(Use several sheets if necessary)</i>		FILING DATE: November 19, 2003	GROUP: 1644

NON-PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/PV/	A	Arnstead et al., "Removal of activated complement from shed blood: comparison of high-and low-dilutional haemofiltration". Acta Anaesthesiol Scand. 1998 Aug;42(7):811-5. ABSTRACT ONLY
/PV/	B	Buono et al., "Influence of C3 Deficiency on Atherosclerosis". Circulation 2002;105;3025-3031
/PV/	C	Carter et al., "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy", Proc. Natl. Acad. Sci USA, Vol 89, pp 4285-4289, May 1992
/PV/	D	Chenoweth, D.E., "Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med, 1981. 304(9): p. 497-503. ABSTRACT ONLY
	E	Clackson et al. "Making antibody fragments using phage display libraries". Nature 352. 624-628 August 15, 1991
/PV/	F	Clardy, C.W., "Complement activation by whole endotoxin is blocked by a monoclonal antibody to factor B." Infect Immun, 1994. 62(10): pp 4549-55
/PV/	G	Dahl et al., "MASP-3 and its association with distinct complexes of the Mannan-Binding Lectin Complement Activation Pathway", Immunity, Vol. 15, 127-135, July 2001
/PV/	H	Dang, "Relationship between developmental stenosis of cervical spinal canal and spinal cord injury", Zhonghua Wai Ke Za Zhi, 1992 Nov;29(12):724-6, 796 ABSTRACT ONLY
/PV/	I	Dreyer, WJ, et al. "Neutrophil accumulation in ischemic canine myocardium. Insights into time course distribution, and mechanism of localization during early reperfusion". Circulation 1991; 84;400-411
/PV/	J	Eaton S., et al. "Assay for Plasma Complement Activation by x-ray contrast media". Invest Radiol, 1990. 25(7):p. 789-92. ABSTRACT ONLY
/PV/	K	Entman, Mark L., et al. "Neutrophil induced oxidative injury of cardiac myocytes", J. Clin. Invest. Vol 90, 1992, p. 1335-1345
/PV/	L	Espinoza, Diego G. et al., "Macrophage Depletion Diminishes Lesion Size and Severity in Experimental Choroidal Neovascularization", Invest Ophthalmol Vis Sci. 2003;44:3586-3592
/PV/	M	Frederick, G.N., L. Truedsson, and A.G. Sjöholm, "New procedure for the detection of complement deficiency by ELISA. Analysis of activation pathways and circumvention of rheumatoid factor influence". J Immunol Methods, 1993: 166(2): p. 263-70 ABSTRACT ONLY
/PV/	N	Gyoten, M., <i>Activation of the complement system and cytokine production by radiographic contrast media in vascular endothelial cell in vitro</i> , Nippon Igaki Hoshasen Gakkai Zasshi, 1998 Dec;58(14):811-5. ABSTRACT ONLY
/PV/	O	Halstensen TS, Brandtzaeg P., <i>Local Complement activation in inflammatory bowel disease</i> , Immunol Res. 1991; 10(3-4): 485-92. ABSTRACT ONLY
	P	Halstensen TS, et al. <i>Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis</i> , Gastroenterology. 1990 May;98(5 pt 1):1264-71.
	Q	Hikawa, Maoshi, et al., <i>Method for production of neuronal hybridoma using emetine and actinomycin D</i> , Brain Research Protocols 1 (1997) 224-226.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.	

MODIFIED FORM PTO-1449 (REV. 6-89)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO.: NMT-8440		SERIAL NO. 10/716,929	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT(S): Rekha Bansal			
				FILING DATE: November 19, 2003		GROUP: 1644	
NON-PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
/PV/	A	Horiuchi, T., et al., <i>Human complement factor B: cDNA cloning, nucleotide sequencing, phenotypic conversion by site-directed mutagenesis and expression</i> . Mol Immunol, 1993. 30 (17): p. 1587-92. ABSTRACT ONLY					
/PV/	B	Hourcade, D.E., L.M. Wagner, and T.J. Oglesby, <i>Analysis of the short consensus repeats of human complement factor B by site-directed mutagenesis</i> . J Biol Chem, 1995. 270 (34): p. 19716-22.					
/PV/	C	Ikeda, Ken et al., <i>Serum lectin with known structure activates complement through the classical pathway</i> , Journal of Biological Chemistry. 1987 262(16): p. 7451-7454					
/PV/	D	Isaacs, J.D., et al., <i>Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential</i> . J Immunol, 1992. 148 (10): p. 3062-71.					
/PV/	E	Jones HM, et al., <i>Cardiopulmonary bypass and complement activation. Involvement of classical and alternative pathways.</i> , Anaesthesia. 1982 Jun;37(6):629-33. ABSTRACT ONLY					
/PV/	F	Jones, Peter T. et al., <i>Replacing the complementarity-determining regions in a human antibody with those from a mouse</i> , Nature 321, 522-525, May 29, 1986 ABSTRACT ONLY					
/PV/	G	Kawana S. et al., <i>Membrane attack complex of complement in Henoch-Schönlein purpura skin and nephritis</i> , Arch Dermatol Res. 1990;282(3):187-7. ABSTRACT ONLY					
/PV/	H	Kilpatrick, David C., <i>Mannan-Binding lectin: clinical significance and applications</i> , Biochimica et Biophysica Acta 1572 (2002) 401-413.					
/PV/	I	Kitano A., et al., <i>New treatment of ulcerative colitis with k-76</i> , Dis Colon Rectum. 1992 Jun;35(6):560-7. ABSTRACT ONLY					
/PV/	J	Kolios G. et al., <i>Mediators of inflammation: production and implication in inflammatory bowel disease</i> . Hepatogastroenterology. 1998 Sept-Oct;45(23):1601-9. ABSTRACT ONLY					
/PV/	K	Lonberg Nils, et al., <i>Antigen-specific human antibodies from mice comprising four distinct genetic modifications</i> , Nature 368, 856-859: April 28, 1994. ABSTRACT ONLY					
/PV/	L	Marks, J.D. et al., <i>By-passing immunization. Human antibodies from v-gene libraries displayed on phage</i> , J Mol Biol. 1991 Dec5;222(3):581-597. ABSTRACT ONLY					
/PV/	M	Moore, F.D., Jr., et al., <i>The effects of complement activation during cardiopulmonary bypass. Attenuation by hypothermia, heparin, and hemodilution</i> . Ann Surg, 1988. 208 (1): p. 95-103. ABSTRACT ONLY					
/PV/	N	Morgan BP et al., <i>Measurement of terminal complement complexes in rheumatoid arthritis</i> , Clin Exp Immunol. 1998 Sep;73(3):473-8. ABSTRACT ONLY					
/PV/	O	Morgan BP, Walport MJ, <i>Complement deficiency and disease</i> , Immunol Today. 1991 Sep;12(9):301-6. ABSTRACT ONLY					
/PV/	P	Morrison SL et al., <i>Chimeric human molecules: mouse antigen-binding domains with human constant region domains</i> , Proc Natl Acad Sci U S A. 1984 Nov;81(21):6851-5. ABSTRACT ONLY					
/PV/	Q	Nakano S, Engel AG, <i>Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients</i> , Neurology. 1993 Jun;43(6):1167-72. ABSTRACT ONLY					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.							

MODIFIED FORM PTO-1449 (REV. 6-89)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO.: NMT-8440		SERIAL NO. 10/716,929	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT(S): Rekha Bansal			
				FILING DATE: November 19, 2003		GROUP: 1644	
NON-PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
/PV/	A	Niculescu F, Rus H. <i>Complement activation and atherosclerosis</i> , Mol Immunol. 1999 Sep-Oct;36(13-14):949-55. ABSTRACT ONLY					
/PV/	B	Pack P. et al., <i>Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli</i> , Biotechnology (NY). 1993 Nov;11(11):1271-7 ABSTRACT ONLY					
/PV/	C	Pangburn, M.K., R.D. Schreiber, and H.J. Muller-Eberhard, <i>Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3</i> . J Exp Med, 1981. 154 (3): p. 856-67. ABSTRACT ONLY					
/PV/	D	Polhill, R.B., Jr., K.M. Pruitt, and R.B. Johnston, Jr., <i>Kinetic assessment of alternative complement pathway activity in a hemolytic system. I. Experimental and mathematical analyses</i> . J Immunol, 1978. 121 (1): p. 363-70.					
/PV/	E	Ravetch, J.V. and J.P. Kinet, <i>Fc receptors</i> . Annu Rev Immunol, 1991. 9 : p. 457-92 ABSTRACT ONLY					
/PV/	F	Sandhu JS, <i>Protein engineering of antibodies</i> , Crit Rev Biotechnol. 1992;12(5-6):437-62. ABSTRACT ONLY					
/PV/	G	Schafer Hansjorg, et al. <i>Deposition of the Terminal C5b-9 Complement Complex in infarcted areas of human Myocardium</i> , Journal of Immun. 1986; 137(6); p. 1945-1949					
/PV/	H	Schmiedt, Walther et al., <i>Complement C6 Deficiency Protects Against Diet-Induced Atherosclerosis in Rabbits</i> , Arterioscler Thromb Vasc Biol. 1998;18:1790-1795.					
/PV/	I	Schulze, M. et al., <i>Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis</i> , Am J Pathol. 1993 Jan;142(1):179-87. ABSTRACT ONLY					
/PV/	J	Seifert PS, et al. <i>Isolation and characterization of a complement-activating lipid extracted from human atherosclerosis lesions</i> , J Exp Med. 1990 Aug 1;172(2):547-57. ABSTRACT ONLY					
/PV/	K	Seifert PS, et al., <i>Generation of Complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position</i> , Mol Immunol. 1987 Dec;24(12):1303-8. ABSTRACT ONLY					
/PV/	L	Seifert PS, et al. <i>The complement system in atherosclerosis</i> , Aththerosclerosis. 1988 Oct;73(2-3):91-104. ABSTRACT ONLY					
/PV/	M	Singer II, et al., <i>Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences</i> , J Immunol. 1993 Apr 1;150(7):2844-57. ABSTRACT ONLY					
/PV/	N	Stevens, John H., et al. <i>Effects of anti-C5a antibodies on the Adult Respiratory Distress Syndrome in Septic Primates</i> , 1986. 77: p. 1812-1816.					
/PV/	O	Tada, T. et al., <i>Membrane attack complex of complement and 20 kDa homologous restriction factor (CD59) in myocardial infarction</i> , Virchows Archiv, 1997. 430(4): p. 327-332. ABSTRACT ONLY					
/PV/	P	Takabayashi T., et al., <i>A new biologic role for C3a and C3a desArg: regulation of TNF-alpha and IL-1 beta synthesis</i> , J Immunol. 1996 May 1;156(9):3455-60. ABSTRACT ONLY					
/PV/	Q	Theil, Steffen et al., <i>Interaction of C1q abd Mannan-Binding Lectin (MBL) with C1r, c1s, MBL-Associated Serine Proteases 1 and 2, and the MBL-Associated Protein MA919</i> , J. Immunol 2000. 165:878-887.					
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.							

MODIFIED FORM PTO-1449 (REV. 6-89)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO.: NMT-8440	SERIAL NO. 10/716,929
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT(S): Rekha Bansal		
		FILING DATE: November 19, 2003	GROUP: 1644	
NON-PATENT LITERATURE DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
/PV/	A	Tomooka K., <i>Serum complement levels in patients with rheumatoid arthritis and vasculitis</i> , Fukuoka Igaku Zasshi. 1989 Oct;80(10):456-66. ABSTRACT ONLY		
/PV/	B	Utley, J.R., <i>Pathophysiology of cardiopulmonary bypass: current issues</i> . J Card Surg, 1990. 5 (3): p. 177-89. ABSTRACT ONLY		
/PV/	C	van de Winkel, J.G. and P.J. Capel, <i>Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications</i> . Immunol Today, 1993. 14 (5): p. 215-21. ABSTRACT ONLY		
	D	Vaughan, T.J., J.K. Osbourn, and P.R. Tempest. <i>Human antibodies by design</i> . Nat Biotechnol, 1998. 16 (6): p. 535-9.		
/PV/	E	Woodruff Trent M., et al., <i>A Potent Human C5a Receptor Antagonist Protects against disease Pathology in a Rat Model of Inflammatory Bowel Disease</i> , J. Immunol. 2003. 171:5514-5520		
/PV/	F	Yasojima, K. et al., <i>Complement Components, but not Complement Inhibitors, Are Upregulated in Atherosclerotic Plaques</i> , Arterioscler. Thromb. Vasc. Biol. 2001;21;1214-1219.		
/PV/	G	Ames, R.S., et al., <i>Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models</i> . J Immunol, 2001. 166 (10): p. 6341-8.		
	H	Hulett, M.D. and P.M. Hogarth, <i>Molecular basis of Fc receptor function</i> . Adv Immunol, 1994. 57 : p. 1-127.		
	I	Lin, Y.F., et al., <i>Cytokine production during hemodialysis: effects of dialytic membrane and complement activation</i> . Am J Nephrol, 1996. 16 (4): p. 293-9. ABSTRACT ONLY		
	J	Liszewski, e a T.C.S.I.F.I. Third Edition, pp. 917-939. W. E. Paul (Ed.). Raven Press: New York.		
	K			
	L			
	M			
	N			
	O			
	P			
	Q			
EXAMINER /F Pierre Vandervegt/		DATE CONSIDERED 03/28/2008		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the patent applicants' attorney.				